LYON, France, Feb. 8, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that an Ablatherm-HIFU device has been installed at the CEDIMAT Center (Centro Diagnóstico, Medicina Avanzada y Telemedicina) in Santo Domingo, Dominican Republic. EDAP's Ablatherm device is distributed in the area through an exclusive contract with Maple Leaf HIFU, assisted by its local partner Solimed. Patients across the area suffering from localized prostate cancer will now be able to benefit from this minimally invasive, robotized Ablatherm-HIFU procedure. Dr. Octavio Cruz Piñeda, Director de la Unidad de Uro-Nefrología y Trasplante Renal de CEDIMAT, commented, "This robotized technique using focused ultrasound is one of the most innovative treatments to address localized prostate cancer. It precisely targets the tumor and preserves patient's quality of life, while avoiding all side effects linked to radical surgery." Dr. Cruz Piñeda successfully treated eight patients, assisted by Dr. Stefan Thüroff, from Harlaching Hospital, Munich, Germany, the most experienced Ablatherm-HIFU operator with more than 2,000 prostate cancer patients treated with HIFU to date. Dr. Thüroff assisted Dr. Piñeda providing recommendations and comprehensive clinical training on the use of robotic Ablatherm-HIFU. This training allowed the clinical team to fully master utilizing HIFU to offer the most effective, minimally invasive treatment to patients with prostate cancer. Ablatherm-HIFU treatment takes less than two hours, patients recover very rapidly from the HIFU procedure, and related side effects are very limited. Marc Oczachowski, EDAP's Chief Executive Officer, added, "I am very pleased that Ablatherm-HIFU technology is gaining momentum in the Caribbean area, offering patients with localized prostate cancer a valid and effective option to address their cancer. We worked closely with our Canadian distributor Maple Leaf HIFU to make our Ablatherm-HIFU technology available in the Caribbean area. We see this as a major step forward in the recognition and adoption of Ablatherm HIFU in this key North American region."